Publication Information

{'id': 'https://openalex.org/W3034449190', 'doi': 'https://doi.org/10.2217/fon-2020-0421', 'title': 'Upcoming first-line chemotherapy for HER2-negative gastric cancer in Japan: which patients benefit from immunotherapy?', 'display_name': 'Upcoming first-line chemotherapy for HER2-negative gastric cancer in Japan: which patients benefit from immunotherapy?', 'publication_year': 2020, 'publication_date': '2020-06-15', 'ids': {'openalex': 'https://openalex.org/W3034449190', 'doi': 'https://doi.org/10.2217/fon-2020-0421', 'mag': '3034449190', 'pmid': 'https://pubmed.ncbi.nlm.nih.gov/32539457'}, 'language': 'en', 'primary_location': {'is_oa': True, 'landing_page_url': 'https://doi.org/10.2217/fon-2020-0421', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S174572715', 'display_name': 'Future Oncology', 'issn_l': '1479-6694', 'issn': ['1479-6694', '1744-8301'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310321119', 'host_organization_name': 'Future Medicine', 'host_organization_lineage': ['https://openalex.org/P4310321119'], 'host_organization_lineage_names': ['Future Medicine'], 'type': 'journal'}, 'license': 'cc-by-nc-nd', 'license_id': 'https://openalex.org/licenses/cc-by-nc-nd', 'version': 'publishedVersion', 'is_accepted': True, 'is_published': True}, 'type': 'article', 'type_crossref': 'journal-article', 'indexed_in': ['crossref'], 'open_access': {'is_oa': True, 'oa_status': 'hybrid', 'oa_url': 'https://doi.org/10.2217/fon-2020-0421', 'any_repository_has_fulltext': False}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5070643359', 'display_name': 'Daisuke Takahari', 'orcid': 'https://orcid.org/0000-0002-2492-6014'}, 'institutions': [{'id': 'https://openalex.org/I42570316', 'display_name': 'Japanese Foundation For Cancer Research', 'ror': 'https://ror.org/00bv64a69', 'country_code': 'JP', 'type': 'nonprofit', 'lineage': ['https://openalex.org/I42570316']}, {'id': 'https://openalex.org/I4210137039', 'display_name': 'The Cancer Institute Hospital', 'ror': 'https://ror.org/03md8p445', 'country_code': 'JP', 'type': 'healthcare', 'lineage': ['https://openalex.org/I4210137039']}, {'id': 'https://openalex.org/I188703185', 'display_name': 'GTx (United States)', 'ror': 'https://ror.org/0400j3f74', 'country_code': 'US', 'type': 'company', 'lineage': ['https://openalex.org/I188703185']}], 'countries': ['JP', 'US'], 'is_corresponding': False, 'raw_author_name': 'Daisuke Takahari', 'raw_affiliation_strings': ['Department of Gastroenterology,The Cancer Institute Hospital of Japanese Foundation for Cancer Research,\rTokyo, Japan', 'Fax: +81 3 3570 0343'], 'affiliations': [{'raw_affiliation_string': 'Department of Gastroenterology,The Cancer Institute Hospital of Japanese Foundation for Cancer Research,\rTokyo, Japan', 'institution_ids': ['https://openalex.org/I42570316', 'https://openalex.org/I4210137039']}, {'raw_affiliation_string': 'Fax: +81 3 3570 0343', 'institution_ids': ['https://openalex.org/I188703185']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5103234751', 'display_name': 'Keisho Chìn', 'orcid': 'https://orcid.org/0000-0002-2015-8185'}, 'institutions': [{'id': 'https://openalex.org/I42570316', 'display_name': 'Japanese Foundation For Cancer Research', 'ror': 'https://ror.org/00bv64a69', 'country_code': 'JP', 'type': 'nonprofit', 'lineage': ['https://openalex.org/I42570316']}, {'id': 'https://openalex.org/I4210137039', 'display_name': 'The Cancer Institute Hospital', 'ror': 'https://ror.org/03md8p445', 'country_code': 'JP', 'type': 'healthcare', 'lineage': ['https://openalex.org/I4210137039']}], 'countries': ['JP'], 'is_corresponding': False, 'raw_author_name': 'Keisho Chin', 'raw_affiliation_strings': ['Department of Gastroenterology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan'], 'affiliations': [{'raw_affiliation_string': 'Department of Gastroenterology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan', 'institution_ids': ['https://openalex.org/I42570316', 'https://openalex.org/I4210137039']}]}, {'author_position': 'last', 'author': {'id': 'https://openalex.org/A5091701897', 'display_name': 'Kensei Yamaguchi', 'orcid': 'https://orcid.org/0000-0001-6887-5709'}, 'institutions': [{'id': 'https://openalex.org/I42570316', 'display_name': 'Japanese Foundation For Cancer Research', 'ror': 'https://ror.org/00bv64a69', 'country_code': 'JP', 'type': 'nonprofit', 'lineage': ['https://openalex.org/I42570316']}, {'id': 'https://openalex.org/I4210137039', 'display_name': 'The Cancer Institute Hospital', 'ror': 'https://ror.org/03md8p445', 'country_code': 'JP', 'type': 'healthcare', 'lineage': ['https://openalex.org/I4210137039']}], 'countries': ['JP'], 'is_corresponding': False, 'raw_author_name': 'Kensei Yamaguchi', 'raw_affiliation_strings': ['Department of Gastroenterology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan'], 'affiliations': [{'raw_affiliation_string': 'Department of Gastroenterology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan', 'institution_ids': ['https://openalex.org/I42570316', 'https://openalex.org/I4210137039']}]}], 'institution_assertions': [], 'countries_distinct_count': 2, 'institutions_distinct_count': 3, 'corresponding_author_ids': [], 'corresponding_institution_ids': [], 'apc_list': None, 'apc_paid': None, 'fwci': 0.286, 'has_fulltext': False, 'cited_by_count': 3, 'citation_normalized_percentile': {'value': 0.732681, 'is_in_top_1_percent': False, 'is_in_top_10_percent': False}, 'cited_by_percentile_year': {'min': 74, 'max': 77}, 'biblio': {'volume': '16', 'issue': '24', 'first_page': '1797', 'last_page': '1799'}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T10696', 'display_name': 'Gastric Cancer Management and Outcomes', 'score': 0.9999, 'subfield': {'id': 'https://openalex.org/subfields/2740', 'display_name': 'Pulmonary and Respiratory Medicine'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, 'topics': [{'id': 'https://openalex.org/T10696', 'display_name': 'Gastric Cancer Management and Outcomes', 'score': 0.9999, 'subfield': {'id': 'https://openalex.org/subfields/2740', 'display_name': 'Pulmonary and Respiratory Medicine'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T11485', 'display_name': 'Gastrointestinal Tumor Research and Treatment', 'score': 0.9962, 'subfield': {'id': 'https://openalex.org/subfields/2715', 'display_name': 'Gastroenterology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}, {'id': 'https://openalex.org/T11067', 'display_name': 'Colorectal Cancer Treatments and Studies', 'score': 0.987, 'subfield': {'id': 'https://openalex.org/subfields/2730', 'display_name': 'Oncology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}], 'keywords': [], 'concepts': [{'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.9220291}, {'id': 'https://openalex.org/C121608353', 'wikidata': 'https://www.wikidata.org/wiki/Q12078', 'display_name': 'Cancer', 'level': 2, 'score': 0.6656821}, {'id': 'https://openalex.org/C2777701055', 'wikidata': 'https://www.wikidata.org/wiki/Q1427096', 'display_name': 'Immunotherapy', 'level': 3, 'score': 0.6594403}, {'id': 'https://openalex.org/C2776694085', 'wikidata': 'https://www.wikidata.org/wiki/Q974135', 'display_name': 'Chemotherapy', 'level': 2, 'score': 0.6262835}, {'id': 'https://openalex.org/C143998085', 'wikidata': 'https://www.wikidata.org/wiki/Q162555', 'display_name': 'Oncology', 'level': 1, 'score': 0.61295396}, {'id': 'https://openalex.org/C126322002', 'wikidata': 'https://www.wikidata.org/wiki/Q11180', 'display_name': 'Internal medicine', 'level': 1, 'score': 0.5543576}], 'mesh': [], 'locations_count': 1, 'locations': [{'is_oa': True, 'landing_page_url': 'https://doi.org/10.2217/fon-2020-0421', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S174572715', 'display_name': 'Future Oncology', 'issn_l': '1479-6694', 'issn': ['1479-6694', '1744-8301'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310321119', 'host_organization_name': 'Future Medicine', 'host_organization_lineage': ['https://openalex.org/P4310321119'], 'host_organization_lineage_names': ['Future Medicine'], 'type': 'journal'}, 'license': 'cc-by-nc-nd', 'license_id': 'https://openalex.org/licenses/cc-by-nc-nd', 'version': 'publishedVersion', 'is_accepted': True, 'is_published': True}], 'best_oa_location': {'is_oa': True, 'landing_page_url': 'https://doi.org/10.2217/fon-2020-0421', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S174572715', 'display_name': 'Future Oncology', 'issn_l': '1479-6694', 'issn': ['1479-6694', '1744-8301'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310321119', 'host_organization_name': 'Future Medicine', 'host_organization_lineage': ['https://openalex.org/P4310321119'], 'host_organization_lineage_names': ['Future Medicine'], 'type': 'journal'}, 'license': 'cc-by-nc-nd', 'license_id': 'https://openalex.org/licenses/cc-by-nc-nd', 'version': 'publishedVersion', 'is_accepted': True, 'is_published': True}, 'sustainable_development_goals': [{'id': 'https://metadata.un.org/sdg/3', 'score': 0.41, 'display_name': 'Good health and well-being'}], 'grants': [{'funder': 'https://openalex.org/F4320311653', 'funder_display_name': 'Taiho Pharmaceutical', 'award_id': None}], 'datasets': [], 'versions': [], 'referenced_works_count': 14, 'referenced_works': ['https://openalex.org/W2099756738', 'https://openalex.org/W2111237964', 'https://openalex.org/W2171075804', 'https://openalex.org/W2187646879', 'https://openalex.org/W2554618897', 'https://openalex.org/W2763064222', 'https://openalex.org/W2801510798', 'https://openalex.org/W2806614796', 'https://openalex.org/W2889646458', 'https://openalex.org/W2909349708', 'https://openalex.org/W2917878197', 'https://openalex.org/W2948169107', 'https://openalex.org/W2954272018', 'https://openalex.org/W2979211828'], 'related_works': ['https://openalex.org/W4362706485', 'https://openalex.org/W4322718939', 'https://openalex.org/W4290617554', 'https://openalex.org/W4206639819', 'https://openalex.org/W4205703606', 'https://openalex.org/W3137670083', 'https://openalex.org/W3008978147', 'https://openalex.org/W2994922817', 'https://openalex.org/W2948610106', 'https://openalex.org/W2552554696'], 'abstract_inverted_index': {'Future': [0, 1857], 'OncologyVol.': [1], '16,': [2, 1864], 'No.': [3, 1830, 1861, 1865], '24': [4, 1729, 1866], 'CommentaryOpen': [5], 'AccessUpcoming': [6], 'first-line': [7, 101, 191, 322, 481, 633, 1069, 1093, 1330, 1577, 1821, 1837], 'chemotherapy': [8, 173, 195, 323, 492, 640, 693, 807, 837, 1070, 1458, 1578, 1608, 1610, 1643, 1645], 'for': [9, 28, 52, 68, 85, 165, 169, 228, 231, 324, 365, 588, 697, 787, 844, 898, 968, 1046, 1281, 1329, 1488, 1611, 1719, 1750, 1780, 1840, 1875], 'HER2-negative': [10, 170, 325, 646, 1085], 'gastric': [11, 108, 143, 166, 1303, 1334, 1375, 1408, 1444, 1492, 1538, 1583, 1613, 1723, 1792], 'cancer': [12, 109, 116, 144, 167, 1271, 1304, 1335, 1448, 1496, 1584, 1687], 'in': [13, 123, 132, 275, 376, 443, 447, 518, 548, 552, 635, 645, 658, 997, 1003, 1020, 1071, 1234, 1245, 1256, 1284, 1370, 1402, 1440, 1534, 1579, 1646, 1661, 1686, 1753, 1788, 1895, 2036, 2047, 2058], 'Japan:': [14], 'which': [15, 255, 653, 664, 737], 'patients': [16, 276, 366, 599, 665, 727, 751, 775, 790, 804, 810, 845, 998, 1021, 1372, 1403, 1441, 1535, 1580, 1647, 1688, 1720, 1754, 1789, 1816], 'benefit': [17, 240, 667, 779], 'from': [18, 241, 668, 780, 1134, 1164, 1189, 1249, 1936, 1966, 1991, 2051], 'immunotherapy?Daisuke': [19], 'Takahari,': [20], 'Keisho': [21, 57], 'Chin': [22, 1207, 1558, 2009], '&': [23, 73, 1125, 1851, 1927], 'Kensei': [24, 74], 'YamaguchiDaisuke': [25], 'Takahari': [26, 1129, 1931], '*Author': [27], 'correspondence:': [29], 'Tel.:': [30], '+81': [31, 36], '3': [32, 37], '3520': [33], '0111;': [34], 'Fax:': [35], '3570': [38], '0343;': [39], 'E-mail': [40], 'Address:': [41], '[email protected]://orcid.org/0000-0002-2492-6014Department': [42], 'of': [43, 49, 59, 65, 76, 82, 140, 155, 175, 197, 216, 251, 269, 281, 286, 303, 384, 475, 478, 556, 630, 641, 677, 716, 721, 730, 754, 793, 820, 853, 874, 904, 951, 995, 1008, 1041, 1054, 1062, 1075, 1084, 1120, 1211, 1259, 1276, 1332, 1568, 1684, 1715, 1806, 1815, 1836, 1922, 2013, 2061], 'Gastroenterology,': [44, 60, 77], 'The': [45, 61, 78, 138, 398, 674, 1052, 1215, 1619, 2017], 'Cancer': [46, 53, 62, 69, 79, 86, 1288, 1299, 1312, 1651, 1694, 1761, 1795], 'Institute': [47, 63, 80], 'Hospital': [48, 64, 81], 'Japanese': [50, 66, 83, 163, 1297], 'Foundation': [51, 67, 84], 'Research,': [54, 70, 87], 'Tokyo,': [55, 71, 88], 'Japan,': [56, 1143, 1170, 1945, 1972], 'ChinDepartment': [58], 'Japan': [72, 136, 377], 'YamaguchiDepartment': [75], 'JapanPublished': [89], 'Online:15': [90], 'Jun': [91], '2020https://doi.org/10.2217/fon-2020-0421AboutSectionsPDF/EPUB': [92], 'ToolsAdd': [93], 'to': [94, 159, 206, 213, 258, 380, 389, 405, 491, 637, 652, 757, 762, 827, 829, 834, 877, 909, 914, 918, 942, 975, 1029, 1037, 1101, 1213, 1656, 1717, 2015], 'favoritesDownload': [95], 'CitationsTrack': [96], 'Citations': [97], 'ShareShare': [98], 'onFacebookTwitterLinkedInReddit': [99], 'Keywords:': [100], 'chemotherapygastric': [102, 1903], 'cancerpembrolizumab': [103, 1904], 'monotherapyTAS-118': [104, 1905], 'plus': [105, 177, 180, 199, 349, 358, 386, 395, 494, 643, 735, 867, 1324, 1364, 1368, 1396, 1400, 1522, 1526, 1532, 1570, 1574, 1906], 'oxaliplatinSOLIn': [106], '2018,': [107], 'was': [110, 353, 374, 403, 489, 515, 983, 1254, 2056], 'the': [111, 119, 124, 160, 186, 190, 202, 207, 214, 217, 248, 252, 266, 328, 371, 382, 465, 468, 476, 519, 539, 578, 605, 631, 638, 649, 686, 695, 739, 964, 986, 993, 1039, 1059, 1066, 1076, 1092, 1099, 1111, 1239, 1246, 1257, 1876, 1913, 2041, 2048, 2059], 'fifth': [112], 'most': [113, 187, 662, 1067], 'commonly': [114], 'diagnosed': [115], 'and': [117, 193, 297, 314, 339, 351, 378, 459, 512, 529, 562, 570, 624, 661, 694, 724, 765, 783, 809, 831, 889, 913, 963, 992, 1043, 1050, 1064, 1150, 1161, 1181, 1186, 1200, 1202, 1278, 1528, 1712, 1808, 1812, 1832, 1952, 1963, 1983, 1988, 2002, 2004], 'had': [118], 'third': [120], 'highest': [121], 'mortality': [122, 1279], 'world.': [125], 'Its': [126], 'incidence': [127, 555, 1277], 'rates': [128, 426], 'are': [129, 185, 679, 683, 767, 824, 832, 954, 1034], 'markedly': [130], 'elevated': [131], 'Eastern': [133], 'Asia,': [134], 'including': [135, 1653], '[1].': [137], 'mainstay': [139], 'unresectable': [141], 'advanced': [142, 1000, 1333, 1374, 1407, 1443, 1491, 1537, 1582, 1612, 1649, 1722, 1791, 1841], '(AGC)': [145], 'treatment': [146, 192, 204, 230, 267, 607, 905, 1083, 1305, 1331, 1787], 'is': [147, 189, 201, 332, 546, 670, 738, 744, 771, 795, 842, 869, 907, 928, 957, 1108, 1680, 1745, 1910], 'chemotherapy,': [148], 'with': [149, 277, 298, 300, 362, 367, 420, 600, 609, 615, 691, 728, 752, 776, 791, 816, 885, 920, 999, 1017, 1023, 1103, 1225, 1230, 1238, 1366, 1373, 1404, 1442, 1536, 1581, 1605, 1640, 1648, 1721, 1755, 1758, 1790, 1817, 2027, 2032, 2040], 'a': [150, 261, 292, 333, 343, 759, 817, 925, 980, 1005, 1118, 1231, 1338, 1415, 1462, 1498, 1540, 1681, 1920, 2033], 'median': [151], 'survival': [152, 1752], 'time': [153], '(MST)': [154], '15–16': [156], 'months.': [157], 'According': [158], 'version': [161], '5': [162], 'guidelines': [164, 1306], '[2],': [168], 'AGC,': [171, 232, 1004], 'doublet': [172, 194, 639], 'consisting': [174, 196], 'fluoropyrimidine': [176, 642, 734, 866, 944], 'platinum': [178, 644, 868], '(S-1': [179], 'cisplatin': [181, 495, 1325, 1367, 1533, 1575], '[SP]': [182], 'or': [183, 227, 283, 360, 591, 822, 850, 887, 930, 946, 1222, 1228, 1235, 1242, 1409, 1445, 1451, 1493, 1606, 1614, 1641, 2024, 2030, 2037, 2044], 'oxaliplatin': [184, 352, 387, 1363, 1529, 1571], 'preferred)': [188], 'ramucirumab': [198], 'paclitaxel': [200, 259, 1397, 1401, 1487], 'second-line': [203, 262], 'according': [205, 212, 1655], 'clinical': [208, 659, 1032, 1810], 'trials': [209, 312, 1033, 1056], '[3–5].': [210], 'Furthermore,': [211, 594], 'results': [215, 320, 399, 620, 1053], 'ATTRACTION-2': [218], 'trial': [219, 373, 470], '[6],': [220], 'nivolumab': [221, 242, 1024, 1718, 1784], 'can': [222, 239], 'be': [223, 272, 628, 656, 785, 878, 896, 940, 1079], 'used': [224], 'as': [225, 260, 289, 393, 480, 714, 856, 871, 1091, 1576, 1785], 'third-line': [226], 'further': [229], 'if': [233, 924], 'applicable.Although': [234], 'specific': [235], 'patient': [236], 'subgroups': [237], 'that': [238, 265, 401, 485, 598, 622, 705, 750, 769, 955], 'immunotherapy': [243, 479, 678, 813, 830, 1042, 1063, 1090], 'have': [244, 317, 758, 1217, 2019], 'not': [245, 583, 614, 671, 934, 958, 972, 1097], 'been': [246, 973], 'identified,': [247], 'subgroup': [249, 521, 595], 'analysis': [250, 596, 1805], 'KEYNOTE-061': [253], 'trial,': [254], 'compared': [256, 690], 'pembrolizumab': [257, 270, 486, 625, 763, 781, 899, 996], 'treatment,': [263, 1094], 'suggested': [264], 'effect': [268, 608], 'might': [271, 939], 'more': [273, 354, 434, 879], 'pronounced': [274], 'performance': [278], 'status': [279, 1660], '(PS)': [280], '0': [282, 794], 'higher': [284], 'levels': [285, 302], 'PD-L1': [287], 'expression,': [288], 'defined': [290], 'by': [291, 1690], 'combined': [293], 'positive': [294], 'score': [295], '(CPS),': [296], 'tumors': [299, 602], 'high': [301], 'microsatellite': [304, 1657], 'instability': [305], '(MSI-H)': [306, 1659], '[7].Most': [307], 'recently,': [308], 'two': [309, 802, 1456], 'Phase': [310, 345, 1339, 1359, 1419, 1466, 1502, 1544, 1565, 1620], 'III': [311, 1340, 1360, 1420, 1467, 1503, 1566, 1621], '(SOLAR': [313, 1585], 'KEYNOTE-062': [315, 469, 1622], 'trial)': [316], 'reported': [318, 471], 'their': [319, 854], 'assessing': [321], 'AGC.': [326, 647, 1086], 'First,': [327], 'SOLAR': [329, 372], 'trial.': [330, 542, 1341, 1421, 1468, 1504, 1546], 'TAS-118': [331, 385, 392, 1569], 'novel': [334], 'oral': [335], 'agent,': [336], 'containing': [337], 'S-1': [338, 348, 357, 394, 1323, 1327, 1365, 1369, 1521, 1525, 1531, 1573], 'leucovorin': [340, 1523, 1527], '(LV).': [341], 'In': [342, 543, 839, 1027], 'randomized': [344], 'II': [346, 1545], 'study,': [347], 'LV': [350, 359, 396], 'active': [355], 'than': [356, 436, 551, 881], 'SP': [361, 406, 437], 'acceptable': [363], 'toxicities': [364], 'AGC': [368, 1047], '[8].': [369], 'Accordingly,': [370], 'conducted': [375], 'Korea': [379], 'evaluate': [381], 'superiority': [383, 585], '(SOL)': [388], 'SP,': [390], 'using': [391], '[9].': [397], 'showed': [400, 604], 'SOL': [402, 432, 444, 623, 770, 841, 875], 'superior': [404], '(MST': [407], '16.0': [408], 'vs': [409, 428, 445, 451, 457, 463, 499, 526, 560, 566, 1644], '15.1': [410], 'months,': [411, 501], 'respectively;': [412, 502, 532], 'hazard': [413], 'ratio': [414], '[HR]:': [415], '0.83;': [416], '95%': [417, 535], 'CI': [418], '0.69–0.99),': [419], 'greater': [421, 860], 'tumor': [422, 711, 818, 855, 861, 891, 969, 978, 990, 1743], 'shrinkage': [423], '(overall': [424], 'response': [425, 688, 761, 906], '73.5': [427], '50.0%,': [429], 'respectively).': [430], 'However,': [431, 648, 774], 'seemed': [433], 'toxic': [435, 880], 'regarding': [438], 'stomatitis': [439], '(grade': [440], '3/4:': [441], '3.7%': [442], '1.4%': [446], 'SP),': [448], 'diarrhea': [449], '(9.4': [450], '4.3%),': [452], 'peripheral': [453], 'sensory': [454], 'neuropathy': [455], '(8.5': [456], '0.3%)': [458], 'weight': [460], 'decreased': [461], '(5.4': [462], '2.9%).On': [464], 'other': [466, 579, 864, 882, 1219, 2021], 'hand,': [467, 580], 'on': [472, 960, 985, 1820, 1872], 'its': [473, 788], 'evaluation': [474, 903], 'efficacy': [477, 994], 'chemotherapy.': [482, 922, 937], 'It': [483, 938], 'found': [484], 'monotherapy': [487, 626, 782, 1025], '(P)': [488], 'noninferior': [490], '(5-FU': [493], '[C];': [496], 'MST': [497, 524], '10.6': [498], '11.1': [500], 'HR:': [503, 533], '0.91;': [504], '99.2%': [505], 'CI:': [506, 536], '0.69–1.18;': [507], 'noninferiority': [508], 'margin': [509], '=': [510], '1.2),': [511], 'this': [513, 952, 1121, 1260, 1923, 2062], 'result': [514], 'also': [516, 603], 'enhanced': [517, 606], 'CPS': [520], '>tenfold': [522], '(CPS>10;': [523], 'P': [525, 549, 610], 'C:': [527], '17.4': [528], '10.8': [530], 'month': [531], '0.69;': [534], '0.49–0.97)': [537], 'like': [538], 'KEYNOTE': [540], '61': [541], 'addition,': [544], 'toxicity': [545, 574], 'milder': [547], 'rather': [550], 'C,': [553, 612], 'lower': [554], 'any': [557, 1226, 2028], 'grade': [558, 563], '(54': [559], '92%)': [561], '3/4': [564], '(16': [565], '68%)': [567], 'adverse': [568], 'events,': [569], 'no': [571, 1209, 1218, 2011, 2020], 'new': [572, 632, 1682], 'immune-related': [573], 'were': [575, 1014], 'observed.': [576], 'On': [577], 'C+P': [581, 616], 'did': [582], 'show': [584], 'over': [586], 'C': [587, 618], 'either': [589], 'CPS>1,': [590], 'CPS>10': [592, 886], '[10].': [593], 'revealed': [597], 'MSI-H': [601, 777, 894], 'versus': [611, 617, 1326, 1398, 1486, 1524, 1530, 1572, 1609], 'but': [613, 681, 901], '[11].These': [619], 'indicated': [621], 'would': [627, 666], 'one': [629], 'treatments': [634], 'addition': [636, 1028], 'exact': [650], 'answer': [651], 'regimens': [654, 1459], 'should': [655, 1078], 'selected': [657], 'practice,': [660], 'importantly,': [663], 'immunotherapy,': [669], 'yet': [672], 'available.': [673], 'long-lasting': [675], 'effects': [676], 'attractive,': [680], 'there': [682, 766], 'concerns': [684, 768], 'about': [685], 'low': [687, 890], 'rate': [689], 'conventional': [692], 'potential': [696], 'hyperprogressive': [698, 1018, 1781], 'disease': [699, 1019, 1679, 1782], '[12].': [700], 'Here,': [701], 'we': [702, 732, 798, 932], 'propose': [703], 'recommendations': [704], 'first': [706, 808], 'consider': [707], 'PS,': [708], 'then': [709], 'CPS,': [710], 'burden': [712, 819, 892, 970, 1814, 1835], '(defined': [713], 'number': [715], 'metastatic': [717], 'sites': [718], 'and/or': [719, 893], 'size': [720, 991, 1744], 'baseline': [722, 989, 1013], 'tumor),': [723], 'MSI': [725], 'status.For': [726], 'PS': [729, 753, 792, 927, 1077], '1,': [731], 'recommend': [733, 935], 'platinum,': [736], 'currently': [740, 1035], 'standard': [741, 936], 'regimen.': [742], 'This': [743], 'because': [745], 'previous': [746, 1457], 'reports': [747], '[7,13]': [748], 'indicate': [749], '1': [755], 'appear': [756], 'poor': [760], 'monotherapy,': [764, 900, 945], 'highly': [772], 'toxic.': [773], 'may': [778, 895], 'will': [784, 1057], 'considered': [786], 'use.For': [789], 'controversial.': [796], 'So,': [797], 'divided': [799], 'them': [800], 'into': [801], 'groups:': [803], 'who': [805, 811, 846], 'receive': [806, 812], 'first.': [814, 838], 'Patients': [815, 884], 'CPS<1': [821], '1≦CPS<10': [823], 'less': [825], 'likely': [826], 'respond': [828], 'recommended': [833, 843], 'undergo': [835], 'cytotoxic': [836, 1044], 'particular,': [840], 'need': [847], 'immediate': [848], 'cytoreduction': [849], 'symptom': [851], 'relief': [852], 'it': [857, 956], 'has': [858, 971, 1130, 1157, 1208, 1932, 1959, 2010], 'provided': [859], 'shrinkage.': [862], 'For': [863], 'patients,': [865], 'recommended,': [870], 'prolonged': [872], 'use': [873], 'appears': [876], 'chemotherapies.': [883], '1≤CPS<10': [888], 'eligible': [897], 'timely': [902], 'important': [908], 'avoid': [910, 915], 'rapid': [911], 'progression': [912, 1685], 'missing': [916], 'opportunities': [917], 'proceed': [919, 1102], 'subsequent': [921, 1104], 'Finally,': [923], "patient's": [926], '2': [929], 'more,': [931], 'do': [933], 'better': [941], 'select': [943], 'best': [947], 'supportive': [948], 'care.The': [949], 'limitations': [950], 'recommendation': [953], 'based': [959], 'sufficient': [961], 'evidence': [962], 'optimal': [965], 'cut-off': [966], 'point': [967], 'identified': [974], 'date.': [976], 'Regarding': [977], 'burden,': [979], 'recent': [981], 'report': [982], 'published': [984], 'correlation': [987], 'between': [988], 'melanoma': [1001, 1756], '[14];': [1002], 'larger': [1006], 'sum': [1007], 'target': [1009], 'lesion': [1010], 'diameter': [1011], 'at': [1012, 1454], 'significantly': [1015], 'associated': [1016], 'treated': [1022, 1406, 1689, 1757], '[15].': [1026], 'KEYNOTE-62,': [1030], 'several': [1031], 'ongoing': [1036], 'investigate': [1038], 'combination': [1040], 'agents': [1045], '(NCT02872116,': [1048], 'NCT02746796': [1049], 'NCT03615326).': [1051], 'these': [1055], 'clarify': [1058], 'appropriate': [1060], 'position': [1061], 'establish': [1065], 'effective': [1068], 'AGC.ConclusionA': [1072], 'careful': [1073], 'assessment': [1074], 'performed': [1080], 'before': [1081], 'initiating': [1082], 'And': [1087], 'when': [1088], 'choosing': [1089], 'make': [1095], 'sure': [1096], 'miss': [1098], 'opportunity': [1100], 'chemotherapy.Open': [1105], 'accessThis': [1106, 1908], 'work': [1107, 1909], 'licensed': [1109, 1911], 'under': [1110, 1912], 'Attribution-NonCommercial-NoDerivatives': [1112, 1914], '4.0': [1113, 1915], 'Unported': [1114, 1916], 'License.': [1115, 1917], 'To': [1116, 1918], 'view': [1117, 1919], 'copy': [1119, 1921], 'license,': [1122, 1924], 'visit': [1123, 1925], 'http://creativecommons.org/licenses/by-nc-nd/4.0/Financial': [1124, 1926], 'competing': [1126, 1928], 'interests': [1127, 1929], 'disclosureD': [1128, 1930], 'received': [1131, 1158, 1933, 1960], 'lecture': [1132, 1162, 1187, 1934, 1964, 1989], 'fees': [1133, 1163, 1188, 1935, 1965, 1990], 'Taiho': [1135, 1165, 1937, 1967], 'Pharmaceutical': [1136, 1139, 1152, 1166, 1172, 1183, 1191, 1938, 1941, 1954, 1968, 1974, 1985, 1993], 'Co.,': [1137, 1140, 1167, 1173, 1939, 1942, 1969, 1975], 'Ono': [1138, 1171, 1940, 1973], 'Eli': [1141, 1168, 1943, 1970], 'Lilly': [1142, 1169, 1944, 1971], 'Bristol-Myers': [1144, 1174, 1946, 1976], 'Squibb,': [1145, 1175, 1947, 1977], 'Yakult': [1146, 1176, 1948, 1978], 'Honsha': [1147, 1177, 1949, 1979], 'Co.': [1148, 1153, 1178, 1184, 1192, 1950, 1955, 1980, 1986, 1994], 'Ltd': [1149, 1185, 1951, 1987], 'Chugai': [1151, 1182, 1953, 1984], 'Ltd,': [1154, 1179, 1193, 1956, 1981, 1995], 'K': [1155, 1206, 1356, 1518, 1957, 2008], 'Yamaguchi': [1156, 1517, 1958], 'research': [1159, 1961], 'grant': [1160, 1962], 'Sanofi': [1180, 1982], 'Takeda': [1190, 1992], 'Bayer,': [1194, 1996], 'Daiichi-Sankyo,': [1195, 1997], 'Dainippon-Sumitomo': [1196, 1998], 'Pharma,': [1197, 1999], 'Merck': [1198, 2000], 'Sharp': [1199, 2001], 'Dohme': [1201, 2003], 'Gilead': [1203, 2005], 'Sciences': [1204, 2006], 'Inc,': [1205, 2007], 'conflict': [1210, 1237, 2012, 2039], 'interest': [1212, 1233, 2014, 2035], 'declare.': [1214, 2016], 'authors': [1216, 2018], 'relevant': [1220, 2022], 'affiliations': [1221, 2023], 'financial': [1223, 1232, 1236, 2025, 2034, 2038], 'involvement': [1224, 2026], 'organization': [1227, 2029], 'entity': [1229, 2031], 'subject': [1240, 2042], 'matter': [1241, 2043], 'materials': [1243, 2045], 'discussed': [1244, 2046], 'manuscript': [1247, 2049], 'apart': [1248, 2050], 'those': [1250, 2052], 'disclosed.No': [1251, 2053], 'writing': [1252, 2054], 'assistance': [1253, 2055], 'utilized': [1255, 2057], 'production': [1258, 2060], 'manuscript.References1.': [1261], 'Bray': [1262], 'F,': [1263], 'Ferlay': [1264], 'J,': [1265, 1596, 1737], 'Soerjomataram': [1266], 'I': [1267], 'et': [1268, 1321, 1357, 1393, 1437, 1483, 1519, 1562, 1602, 1637, 1676, 1709, 1740, 1776], 'al.': [1269, 1322, 1358, 1394, 1438, 1484, 1520, 1563, 1603, 1638, 1677, 1710, 1741, 1777], 'Global': [1270], 'statistics': [1272], '2018:': [1273], 'GLOBOCAN': [1274], 'estimates': [1275], 'worldwide': [1280], '36': [1282], 'cancers': [1283, 1819], '185': [1285], 'countries.': [1286], 'CA': [1287], 'J.': [1289, 1624, 1725], 'Clin.': [1290, 1625, 1693, 1760], '68(6),': [1291], '394–424': [1292], '(2018).Crossref,': [1293, 1508, 1765], 'Medline,': [1294, 1347, 1382, 1427, 1473, 1509, 1552, 1699, 1731, 1766, 1799], 'Google': [1295, 1349, 1384, 1429, 1475, 1511, 1554, 1593, 1701, 1732, 1768, 1801], 'Scholar2.': [1296], 'Gastric': [1298, 1311, 1794], 'Association.': [1300], 'In:': [1301], 'apanese': [1302], '2018': [1307], '5th': [1308], 'English': [1309], 'Edition.': [1310], '(2020).Google': [1313], 'Scholar3.': [1314], 'Koizumi': [1315], 'W,': [1316], 'Narahara': [1317], 'H,': [1318, 1387], 'Hara': [1319], 'T': [1320, 1436], 'alone': [1328], '(SPIRITS': [1336], 'trial):': [1337], 'Lancet': [1342, 1422, 1469, 1505, 1547], 'Oncol.': [1343, 1378, 1423, 1548, 1588, 1626, 1664], '9(3),': [1344], '215–221': [1345], '(2008).Crossref,': [1346], 'CAS,': [1348, 1383, 1428, 1474, 1510, 1553, 1700, 1767, 1800], 'Scholar4.': [1350], 'Yamada': [1351], 'Y,': [1352, 1773], 'Higuchi': [1353], 'K,': [1354, 1389, 1478, 1559, 1631], 'Nishikawa': [1355], 'study': [1361, 1567], 'comparing': [1362], 'chemotherapy-naïve': [1371], 'cancer.': [1376, 1724, 1793], 'Ann.': [1377, 1587, 1663], '26(1),': [1379], '141–148': [1380], '(2015).Crossref,': [1381], 'Scholar5.': [1385], 'Wilke': [1386], 'Muro': [1388], 'Van': [1390, 1597, 1632], 'Cutsem': [1391, 1598, 1633], 'E': [1392], 'Ramucirumab': [1395], 'placebo': [1399], 'previously': [1405, 1489], 'gastro-': [1410], 'oesophageal': [1411], 'junction': [1412, 1447, 1495, 1616], 'adenocarcinoma': [1413], '(RAINBOW):': [1414], 'double-': [1416], 'blind,': [1417], 'randomised': [1418], '15(11),': [1424], '1224–1235': [1425], '(2014).Crossref,': [1426], 'Scholar6.': [1430], 'Kang': [1431, 1556], 'YK,': [1432, 1557], 'Boku': [1433], 'N,': [1434, 1516], 'Satoh': [1435], 'Nivolumab': [1439], 'gastro-oesophageal': [1446, 1494], 'refractory': [1449], 'to,': [1450], 'intolerant': [1452], 'of,': [1453], 'least': [1455], '(ONO-4538-12,': [1460], 'ATTRACTION-2):': [1461], 'randomised,': [1463, 1499, 1541], 'double-blind,': [1464], 'placebo-controlled,': [1465], '390(10111),': [1470], '2461–2471': [1471], '(2017).Crossref,': [1472, 1698], 'Scholar7.': [1476], 'Shitara': [1477, 1630], 'Özgüroğlu': [1479], 'M,': [1480], 'Bang': [1481, 1600, 1635], 'YJ': [1482, 1601], 'Pembrolizumab': [1485, 1604, 1639], 'treated,': [1490], '(KEYNOTE-061):': [1497], 'open-label,': [1500, 1543], 'controlled,': [1501], '392(10142),': [1506], '123–133': [1507], 'Scholar8.': [1512], 'Hironaka': [1513], 'S,': [1514, 1671, 1704], 'Sugimoto': [1515], 'cancer:': [1539], 'multicentre,': [1542], '17(1),': [1549], '99–108': [1550], '(2016).Crossref,': [1551], 'Scholar9.': [1555], 'Chung': [1560], 'H': [1561], 'A': [1564], 'study).': [1586], '30(Suppl.': [1589, 1665], '4),': [1590], 'IV153': [1591], '(2019).Crossref,': [1592, 1730, 1798], 'Scholar10.': [1594], 'Tabernero': [1595], 'E,': [1599, 1634], 'without': [1607, 1642], 'gastroesophageal': [1615, 1818, 1842], '(G/GEJ)': [1617], 'adenocarcinoma:': [1618], 'study.': [1623], '37(18S)': [1627], '(2019).Google': [1628, 1668], 'Scholar11.': [1629], 'Y-J': [1636], 'G/GEJ': [1650], '(GC)': [1652], 'outcomes': [1654], 'instability-high': [1658], 'KEYNOTE-062.': [1662], '5),': [1666], 'v851–v934': [1667], 'Scholar12.': [1669], 'Champiat': [1670], 'Dercle': [1672], 'L,': [1673], 'Ammari': [1674], 'S': [1675, 1775], 'Hyperprogressive': [1678], 'pattern': [1683], 'anti-PD-1/': [1691], 'PD-L1.': [1692], 'Res.': [1695, 1762], '23(8),': [1696], '1920–1928': [1697], 'Scholar13.': [1702], 'Mishima': [1703, 1774], 'Kawazoe': [1705], 'A,': [1706, 1771], 'Nakamura': [1707, 1772], 'Y': [1708], 'Clinicopathological': [1711], 'molecular': [1713], 'features': [1714], 'responders': [1716], 'Immunother.': [1726], 'Cancer.': [1727], '7(1),': [1728], 'Scholar14.': [1733], 'Joseph': [1734], 'RW,': [1735], 'Elassaiss-Schaap': [1736], 'Kefford': [1738], 'R': [1739], 'Baseline': [1742], 'an': [1746], 'independent': [1747], 'prognostic': [1748], 'factor': [1749], 'overall': [1751], 'pembrolizumab.': [1759], '24(20),': [1763], '4960–4967': [1764], 'Scholar15.': [1769], 'Sasaki': [1770], 'Predictive': [1778], 'factors': [1779], 'during': [1783], 'anti-PD1': [1786], '22(4),': [1796], '793–802': [1797], 'ScholarFiguresReferencesRelatedDetailsCited': [1802], 'ByGlobal': [1803], 'retrospective': [1804], 'clinician-': [1807], 'patient-reported': [1809], 'characteristics': [1811], 'humanistic': [1813], 'treatment23': [1822], 'February': [1823], '2023': [1824], '|': [1825, 1856], 'BMC': [1826], 'Cancer,': [1827], 'Vol.': [1828, 1859, 1863], '23,': [1829], '1Patient': [1831], 'caregiver': [1833], 'socioeconomic': [1834], 'systemic': [1838], 'therapy': [1839], 'adenocarcinomaHong': [1843], 'Xiao,': [1844], 'David': [1845], 'Bertwistle,': [1846], 'Keerun': [1847], 'Khela,': [1848], 'Chloe': [1849], 'Middleton-Dalby': [1850], 'Jennifer': [1852], 'Hall5': [1853], 'January': [1854], '2022': [1855], 'Oncology,': [1858], '18,': [1860], '10': [1862], 'eToC': [1867], 'Sign': [1868], 'up': [1869], 'Follow': [1870], 'us': [1871], 'social': [1873], 'media': [1874], 'latest': [1877], 'updates': [1878], 'Metrics': [1879], 'History': [1880], 'Received': [1881], '29': [1882], 'April': [1883], '2020': [1884, 1888, 1893, 1898, 1900], 'Accepted': [1885], '20': [1886], 'May': [1887], 'Published': [1889, 1894], 'online': [1890], '15': [1891], 'June': [1892], 'print': [1896], 'August': [1897], 'Information©': [1899], 'Daisuke': [1901], 'TakahariKeywordsfirst-line': [1902], 'oxaliplatinSOLOpen': [1907], 'manuscript.PDF': [2063], 'download': [2064]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W3034449190', 'counts_by_year': [{'year': 2024, 'cited_by_count': 1}, {'year': 2023, 'cited_by_count': 1}, {'year': 2022, 'cited_by_count': 1}], 'updated_date': '2024-12-12T13:17:41.229727', 'created_date': '2020-06-19'}